Anti-MRSA effects of synergism of recombinant lysostaphin with biosynthesized silver nanoparticles.

Background: Methicillin-resistant Staphylococcus aureus (MRSA) strains become a major challenge to public health and health provider due to their wide spread and resistance to wide spectrum of antibacterial agents.
Aim: This study aimed to characterize recombinant lysostaphin produced by Escherichia coli BL21(DE3) and to investigate the biosynthesis of silver nanoparticles (SNPs) by Candida albicans against MRSA.
Methods: Samples were collected from vaginal samples. The methods included efficient cloning, expression, and purification of recombinant lysostaphin, a potent antibacterial enzyme targeting S. aureus , and achieved with advanced molecular techniques in E. coli BL21(DE3). The SNPs were synthesized using a biogenic approach with C. albicans , demonstrating stable and efficient silver ion reduction, as confirmed by ultraviolet-visible spectroscopy, scanning electron microscope, and Fourier-transform infrared spectroscopy (FTIR) analyses.
Results: The antibacterial assays against MRSA strains of S. aureus showed significant inhibition by both lysostaphin and SNPs. The combination of biosynthesized SNPs/polyethylene glycol with lysostaphin exerted significant activity against tested bacteria, resulting in zone of growth inhibition of 20.33 ± 0.88 mm.
Conclusion: These findings suggest a promising synergistic antibacterial strategy, offering hope in the fight against MRSA. The study findings reveal that lysostaphin and SNPs could be effective in the treatment of MRSA-related infections, especially when used in combination.
Competing Interests: There is no conflict of interest in the current study.